XEVMPD Guide for Pharmacovigilance Professionals

A documented warning assessment with an approved rationale A validation report showing that required fields, controlled terms and business rules were checked No evidence that validation checks were performed before submission A controlled archive containing the submitted XML and receipt

Only a new signal identified in EVDAS A variation, withdrawal, name change or other regulatory or product-lifecycle change Only an annual financial close Only a change to the company's organisational chart

To replace the need for source regulatory documents To demonstrate how internal master data are translated into specific XEVMPD elements To calculate the benefit-risk balance of the medicinal product To record only the names of personnel trained in XML editing

Personally entering every product record into XEVMPD Delegating all product data matters without receiving performance or issue information Ensuring that governance, controls, review and escalation arrangements are defined and effective Approving product names without reference to regulatory source documents

Use the internally preferred abbreviation because country formatting is optional Confirm the official number against the national authorisation document, correct the mapping and retain the correction evidence Remove the MA number and rely on the trade name Submit the incorrect value and wait for a safety report to identify the issue

Submit immediately using existing internal data, then create documentation only if EMA rejects it Collect authoritative sources, map fields, validate, obtain approval, submit, monitor the response and reconcile the processed record Wait until the first adverse reaction report is received before creating the product record Create a product record using the trade name alone and add authorisation details later

Assume the record is acceptable because it was transmitted Review the returned errors, correct the underlying data, document the corrective action and resubmit promptly Create a second unrelated product record to bypass the error Close the change control because submission has already occurred

It provides reliable product references for grouping and analysing adverse reaction reports It replaces statistical analysis performed in EVDAS It determines the clinical significance of every individual case It authorises the regulatory action resulting from a confirmed signal

It stores and analyses individual adverse reaction reports It stores structured medicinal product information used to identify and standardise products It replaces the need for national marketing authorisation databases It determines whether an individual adverse reaction is medically serious

The outdated status may cause incorrect interpretation of product availability in regulatory and pharmacovigilance processes The withdrawal will automatically be removed from the national authorisation record The product's active substance will necessarily change The error can only affect commercial forecasting and cannot affect pharmacovigilance